AbbVie is stumping up more than $188 per share for Ireland-domiciled Allergan, best known for wrinkle treatment Botox, which is a 45% premium to its closing price before the deal was announced.

Skyrizi and Rinvoq use in gastroenterology grew over 40% year-over-year. Cantor gave AbbVie an Overweight rating with a $210 price target. Markets are messy—but the right setups can still ...

A report by the Senate Finance Committee has concluded that AbbVie exploited a financial loophole introduced by former President Donald Trump in 2017 to avoid paying "billions in taxes." The ...

AbbVie (NYSE:ABBV) is scheduled to announce its earnings on Friday, April 25, 2025. Currently, the company holds a market capitalization of $307 billion. Over the past twelve months, AbbVie ...

Botox now has competitors making chemically similar products – rival drugs include Dysport, produced by France’s Ipsen and Xeomin from Germany’s Merz. But AbbVie says it is confident it can ...

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...

In the latest market close, AbbVie (ABBV) reached $170.16, with a -1.64% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 2.36% for the day.

Paradigm Micro-Cap Fund earns an Above Average Process Pillar rating. The most important driver of the rating is the fund's strong long-term risk-adjusted performance. This can be seen in its five ...

They have been bothering me for so long, I was literally considering options like Botox, and I am only 21... This moisturizer has been a godsend." Smooth the look of deep wrinkles with this ...

Analysts' ratings for AbbVie ABBV over the last quarter vary ... added several new products and drugs in aesthetics (including Botox). Market Capitalization Analysis: Above industry benchmarks ...